

**Genzyme key products: consolidated sales by geographic region - 2011**

<b>Q1 2011 net sales * (€million)</b>	<b>Western Europe</b>	<b>United States</b>	<b>Emerging Markets</b>	<b>Rest of the World</b>	<b>TOTAL</b>
Cerezyme®	55	37	34	13	139
Myozyme®/Lumizyme®	54	21	12	7	94
Fabrazyme®	8	13	4	5	30
Other Rare Diseases products **	22	28	15	16	81
<b>Total Rare Diseases</b>	<b>139</b>	<b>99</b>	<b>65</b>	<b>41</b>	<b>344</b>
Renage®/Renvela®	33	84	11	3	131
Synvisc®/Synvisc One®	6	53	3	8	70

  

<b>Q2 2011 consolidated net sales (€million)</b>	<b>Western Europe</b>	<b>United States</b>	<b>Emerging Markets</b>	<b>Rest of the World</b>	<b>TOTAL</b>
Cerezyme®	61	42	48	15	166
Myozyme®/Lumizyme®	58	25	10	6	99
Fabrazyme®	7	13	4	6	30
Other Rare Diseases products **	18	29	13	19	79
<b>Total Rare Diseases</b>	<b>144</b>	<b>109</b>	<b>75</b>	<b>46</b>	<b>374</b>
Renage®/Renvela®	35	80	12	10	137
Synvisc®/Synvisc One®	6	69	5	9	89

  

<b>Q3 2011 consolidated net sales (€million)</b>	<b>Western Europe</b>	<b>United States</b>	<b>Emerging Markets</b>	<b>Rest of the World</b>	<b>TOTAL</b>
Cerezyme®	44	40	43	14	141
Myozyme®/Lumizyme®	57	26	12	6	101
Fabrazyme®	7	10	5	10	32
Other Rare Diseases products **	18	30	18	20	86
<b>Total Rare Diseases</b>	<b>126</b>	<b>106</b>	<b>78</b>	<b>50</b>	<b>360</b>
Renage®/Renvela®	31	86	12	6	135
Synvisc®/Synvisc One®	5	66	4	5	80

  

<b>Q4 2011 consolidated net sales (€million)</b>	<b>Western Europe</b>	<b>United States</b>	<b>Emerging Markets</b>	<b>Rest of the World</b>	<b>TOTAL</b>
Cerezyme®	51	25	44	13	133
Myozyme®/Lumizyme®	61	29	11	7	108
Fabrazyme®	9	25	5	8	47
Other Rare Diseases products **	22	34	21	23	100
<b>Total Rare Diseases</b>	<b>143</b>	<b>113</b>	<b>81</b>	<b>51</b>	<b>388</b>
Renage®/Renvela®	32	99	6	6	143
Synvisc®/Synvisc One®	5	76	4	2	87

  

<b>2011 net sales * (€million)</b>	<b>Western Europe</b>	<b>United States</b>	<b>Emerging Markets</b>	<b>Rest of the World</b>	<b>TOTAL</b>
Cerezyme®	211	144	169	55	579
Myozyme®/Lumizyme®	230	101	45	26	402
Fabrazyme®	31	61	18	29	139
Other Rare Diseases products **	80	121	67	78	346
<b>Total Rare Diseases</b>	<b>552</b>	<b>427</b>	<b>299</b>	<b>188</b>	<b>1,466</b>
Renage®/Renvela®	131	349	41	25	546
Synvisc®/Synvisc One®	22	264	16	24	326

\* Q1 2011 sales were not consolidated by Sanofi

\*\* Other Rare Diseases products include Cholestagel, Welchol, Aldurazyme, Elapraxe, Thyrogen

From 2012, Sanofi financial press releases will include Genzyme sales, consisting of Rare Diseases products (Cerezyme<sup>®</sup>, Myozyme<sup>®</sup>/Lumizyme<sup>®</sup>, Fabrazyme<sup>®</sup> and Other Rare Diseases products) and Multiple Sclerosis products.

Sanofi will continue to provide sales of Renagel<sup>®</sup>/Renvela<sup>®</sup> and Synvisc<sup>®</sup>/Synvisc One<sup>®</sup> which are now part of Sanofi pharmaceuticals.